# Timing of Start of systemIc Treatment for Asymptomatic Metastasized Pancreatic Cancer

> **NCT04897854** · PHASE3 · UNKNOWN · sponsor: **Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)** · enrollment: 184 (estimated)

## Conditions studied

- Metastatic Pancreas Cancer

## Interventions

- **DRUG:** Folfirinox

## Key facts

- **NCT ID:** NCT04897854
- **Lead sponsor:** Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-22
- **Primary completion:** 2024-04-22
- **Final completion:** 2024-04-22
- **Target enrollment:** 184 (ESTIMATED)
- **Last updated:** 2021-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04897854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04897854, "Timing of Start of systemIc Treatment for Asymptomatic Metastasized Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04897854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*